NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
Clinical Trials
12 trialsNCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT06712472 2026-01-20
RAINBO-RED
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT02755844 2025-10-02
ENDOLA
Hospices Civils de Lyon
Phase 1/2 Completed
NCT05320757 2025-06-11
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
The University of Hong Kong
Phase EARLY_PHASE1 Completed
NCT03745950 2024-12-04
UTOLA
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT05255653 2024-11-29
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT03924245 2022-04-04
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT03951415 2021-04-01
DOMEC
Leiden University Medical Center
Phase 2 Unknown
NCT02506816 2020-11-30
Polen
MedSIR
Completed